- PR Newswire•19 hours ago
FRANKLIN LAKES, N.J., Jan. 17, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced the commercial availability of its new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research. The process of whole transcriptome analysis (WTA) is typically used by researchers in the discovery phase to determine if an under- or over-expression of certain genes are indicative of a specific set of physical characteristics, or phenotype. Being able to quantify RNA molecules that comprise genes is a critical early stage process to determine what makes healthy cells different from diseased cells, for example, or to gain a greater understanding of the underlying causes of cell differentiation.
- Capital Cube•7 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Becton, Dickinson & Co. a score of 56. Our analysis is based on comparing Becton, Dickinson & Co. with the following peers – Thermo Fisher Scientific Inc., DENTSPLY SIRONA, Inc., Intuitive Surgical, Inc., C. R. Bard, Inc., Hologic, Inc., ResMed Inc., Baxter International Inc., Varian Medical Systems, ... Read more (Read more...)
- Accesswire•7 days ago
Upcoming AWS Coverage on Becton, Dickinson and Co. LONDON, UK / ACCESSWIRE / January 11, 2017 / Active Wall St. announces its post-earnings coverage on AngioDynamics, Inc. (NASDAQ: ANGO ). The Company ...
BDX : Summary for Becton, Dickinson and Company C - Yahoo Finance
Becton, Dickinson and Company (BDX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||171.31 - 173.87|
|52 Week Range||129.50 - 181.76|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||38.62|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|